A sentence was omitted from Section 2.2 of the Methods. The corrected paragraph should read: DMEM, bovine serum and penicillin/streptomycin were purchased from Hyclone (Logan, UT). Nilotinib (TasignaR) (Fig. 1B) was obtained as a gift from Novartis pharmaceuticals (Basel, Switzerland). Imatinib (Fig. 1A) and dasatinib (Fig. 1C) were purchased from ChemieTeck Inc. (Indianapolis, IN). Paclitaxel, vincristine, doxorubicin, colchicine, p-aminophenylmethylsulfonyl fluoride, bovine serum albumin, dimethyl sulfoxide (DMSO) and 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT), the monoclonal mouse antibody against P-gp (P7965), the secondary horseradish peroxidase-labeled anti-goat or anti-mouse IgG were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). A polyclonal goat antibody against human MRP7 (D-19) was purchased from Santa Cruz Biotech Inc. (Santa Cruz, CA). A polyclonal antibody against human MRP1/ABCC1 was kindly provided by Dr. Akiyama (Kagoshima University, Japan) [21]. A monoclonal antibody BXP-34 against BCRP was acquired from Signet Laboratories Inc. (Dedham, MA). [3H]-paclitaxel (45 μCi/mmol) was purchased from Moravek Biochemicals (Brea, CA).
Citation: Shen T, Kuang Y-H, Ashby CR Jr, Lei Y, Chen A, Zhou Y, et al. (2009) Correction: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). PLoS ONE 4(11): 10.1371/annotation/e57b4610-9029-48db-9d57-5cc0fa35b8ac. https://doi.org/10.1371/annotation/e57b4610-9029-48db-9d57-5cc0fa35b8ac
Published: November 12, 2009
Copyright: © 2009 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.